United Therapeutics: UBS Maintains Buy, Raises PT to $560 from $415.
ByAinvest
Thursday, Sep 4, 2025 8:49 am ET1min read
UBS--
The positive trial outcomes have led UBS to increase its risk-adjusted peak sales forecast for Tyvaso in IPF to $3.3 billion from $1.5 billion. The drug's potential to become a standard of care in the $4 billion global IPF market is cited as a key factor driving this forecast increase [2].
UBS has identified several upcoming catalysts for United Therapeutics, including the detailed TETON-2 results presentation at the ERS Congress on September 28 and the TETON-1 trial readout expected in the first half of 2026. Additionally, the company has expanded its partnership with MannKind Corporation to develop a second dry powder inhalation therapy, further bolstering its treatment offerings [2].
Other analysts have also responded positively to the trial results. Jefferies has raised its price target for United Therapeutics to $564, maintaining a "Buy" rating, while Cantor Fitzgerald continues to support the stock with an "Overweight" rating and a $405 price target [2].
United Therapeutics' strong financial health, with an "Excellent" InvestingPro overall score of 3.98, and impressive gross profit margins of 89% further underscore the company's potential [2].
References:
[1] https://www.marketbeat.com/instant-alerts/heico-nysehei-price-target-raised-to-37500-at-ubs-group-2025-08-27/
[2] https://www.investing.com/news/analyst-ratings/united-therapeutics-stock-price-target-raised-to-560-from-415-at-ubs-93CH-4223939
UTHR--
United Therapeutics: UBS Maintains Buy, Raises PT to $560 from $415.
UBS Group has maintained its "Buy" rating on United Therapeutics Corp. (NASDAQ: UTHR) while raising its price target to $560 from $415. This move comes following the successful Phase 3 TETON-2 trial results, which demonstrated significant improvements in forced vital capacity compared to a placebo for idiopathic pulmonary fibrosis (IPF) patients [2].The positive trial outcomes have led UBS to increase its risk-adjusted peak sales forecast for Tyvaso in IPF to $3.3 billion from $1.5 billion. The drug's potential to become a standard of care in the $4 billion global IPF market is cited as a key factor driving this forecast increase [2].
UBS has identified several upcoming catalysts for United Therapeutics, including the detailed TETON-2 results presentation at the ERS Congress on September 28 and the TETON-1 trial readout expected in the first half of 2026. Additionally, the company has expanded its partnership with MannKind Corporation to develop a second dry powder inhalation therapy, further bolstering its treatment offerings [2].
Other analysts have also responded positively to the trial results. Jefferies has raised its price target for United Therapeutics to $564, maintaining a "Buy" rating, while Cantor Fitzgerald continues to support the stock with an "Overweight" rating and a $405 price target [2].
United Therapeutics' strong financial health, with an "Excellent" InvestingPro overall score of 3.98, and impressive gross profit margins of 89% further underscore the company's potential [2].
References:
[1] https://www.marketbeat.com/instant-alerts/heico-nysehei-price-target-raised-to-37500-at-ubs-group-2025-08-27/
[2] https://www.investing.com/news/analyst-ratings/united-therapeutics-stock-price-target-raised-to-560-from-415-at-ubs-93CH-4223939
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet